Evidence map›Paper›PMID 39931586›Full record

ArticleCureus2025

Secondary Iron Overload Due to Amino Acid Chelated Iron Supplementation: A Case Report Involving a Mother and Daughter.

Naomi Sugimori, Yoh Jinnouchi, Toru Mizoguchi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Naomi SugimoriDepartment of Hematology, Sugimori Clinic, Takaoka, JPN.
Yoh JinnouchiOrthomolecular Medical Nutrition Therapy, Mizoguchi Clinic, Tokyo, JPN.
Toru MizoguchiOrthomolecular Medical Nutrition Therapy, Mizoguchi Clinic, Tokyo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amino acid chelated iron (bisglycinate chelate iron, Ferrochel) has been developed and used as a food fortifier to prevent and treat iron deficiency anemia. However, its long-term use has not been described and reports of iron overload are unavailable. We report a case of a mother and daughter who were diagnosed with iron overload based on blood sampling. Serum analysis revealed elevated ferritin levels and increased transferrin saturation (TSAT). MRI of the daughter showed iron accumulation in the liver, spleen, and bone marrow with normal inflammatory response and no findings suggestive of collagen disease or tumor, and she was diagnosed with secondary iron overload due to oral administration of an amino acid chelated iron preparation. After discontinuing over-the-counter medications and approximately two years of phlebotomy, the women showed a trend toward improvement in their hematologic profiles. Although amino acid chelated iron supplements can be easily administered without side effects such as nausea, ferritin levels should be checked if they are administered for more than a year. Even asymptomatic patients may suffer from iron overload, which can be very dangerous if left untreated. Therefore, amino acid chelated iron should be considered as medicine rather than as a supplement, and immediate action is needed in these cases. This report highlights the importance of careful medication review of over-the-counter amino acid chelated iron supplements.

Indexed as

amino acid chelated ironferrochelferrous amino acid chelateferrous bisglycinateferrous bisglycinate chelateironiron bisglycinate chelateiron overloadiron supplementationiron supplements

Identifiers

PMID39931586
PMCPMC11808287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.